Marc A. Cohen - 22 Jun 2022 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Reporting relationship: Director
Issuer ticker: CCCC
Reported as of: 22 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2022, 16:15:36 UTC
Prior SEC filing: 23 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Jolie M. Siegel, Attorney-in-Fact

Key filing fact

Marc A. Cohen filed Form 4 for C4 Therapeutics, Inc. (CCCC) on 23 Jun 2022.

Key facts

This page summarizes Marc A. Cohen's Form 4 filing for C4 Therapeutics, Inc. (CCCC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jun 2022, 16:15.

Change

Previous filing in this sequence was filed on 23 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CCCC transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +23,500
Change %
Price: $0.000000
Shares after: 23,500
Date: 22 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,500
Exercise price: $6.06
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders.